Moteur de recherche d’entreprises européennes

Financement de l’UE (7 941 665 €) : Children’s Liver Tumour European Research Network Hor01/01/2016 Programme de recherche et d'innovation de l'UE « Horizon »

Texte

Children’s Liver Tumour European Research Network

Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying cirrhotic liver diseases. The ChiLTERN project relates to topic PHC 18 ‘establishing effectiveness of health care interventions in the paediatric population’. The ChiLTERN project builds on a unique opportunity to undertake a comprehensive research programme linked to an ambitious global partnership which will see the single largest clinical trial (the Paediatric Hepatic International Tumour Trial - PHITT) ever undertaken in this population of patients, with several randomised questions in six subgroups of patients. ChiLTERN will allow us to move towards an era of personalised therapy in which each patient will receive the correct amount of chemotherapy and will undergo has the best surgical operation (surgical resection or liver transplant). By using both clinical and biological information, we can assign patients more accurately to risk groups based on their survival. Using genetic tests and biomarkers, we will determine those children who may be at risk of developing long term side effects (deafness, heart failure, kidney damage). In addition, biomarkers will allow us to monitor during therapy and detect toxicities early before serious damage is done so that we can adapt treatment and prevent these problems. Finally, we will be using imaging technology tools which will help our surgeons plan liver operations more safely and effectively. Ultimately ChiLTERN will allow us to cure more children with liver cancer, expose fewer children to toxic chemotherapy and ensure their surgery is both effective and safe.


Azienda Ospedale Universita Padova 170 875 €
Centre Hospitalier Universitaire de Rennes 472 356 €
Children's Health Ireland 92 263 €
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL 15 606,00 €
Cineca Consorzio Interuniversitario 333 750 €
CLALIT HEALTH SERVICES 20 000 €
Cliniques Universitaires Saint-LUC ASBL 236 402 €
EBERHARD KARLS UNIVERSITAET TUEBINGEN 408 050 €
Fakultni Nemocnice V Motole 36 725 €
Fundacion para La Investigacion Biomedica de Cordoba 0,00 €
Gdanski Uniwersytet Medyczny 181 425 €
Institut de Investigacio en Ciencies de La Salut Germans Trias i Pujol 1 209 548 €
Istituto Di Ricerca Pediatrica Citta Della Speranza 100 000 €
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN 762 250 €
MEVIS MEDICAL SOLUTIONS AG 75 000 €
Oslo Universitetssykehus HF 107 388 €
Ospedale Pediatrico Bambino Gesu 71 365 €
POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA 20 000 €
PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE B.V. 48 000 €
SCHWEIZERISCHE PADIATRISCHE ONKOLOGIE GRUPPE (SPOG) 0,00 €
Servicio Andaluz de Salud 211 625 €
ST. Anna Kinderkrebsforschung GmbH 20 075 €
ST Anna Kinderkrebsforschung Verein 0,00 €
The University of Birmingham 2 676 440 €
Universita Degli Studi Di Padova 11 759,50 €
Universitaetsklinikum Tuebingen 0,00 €
UNIVERSITATSKLINIKUM BONN 337 133 €
University of Newcastle Upon Tyne 119 055 €
Vastra Gotalandsregionen 117 825 €
Xentech SAS 86 750 €

https://cordis.europa.eu/project/id/668596

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.

Creative Commons License Les visualisations de "Azienda Ospedale Universita Padova - Financement de l’UE (7 941 665 €) : Children’s Liver Tumour European Research Network" sont mis à disposition par North Data et peuvent être réutilisées selon les termes de la licence Creative Commons CC-BY.